# US 2019/0314489 A1 · Cells for producing influenza virus and method for producing influenza virus

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2019/0314489 A1
- Document ID: US20190314489A1
- Status: Published application
- Kind: A1
- Application number: 16/453,464
- Filed: 2019-06-26
- Published: 2019-10-17
- Earliest claimed: 2014-09-22
- Assignees: Japan Science and Technology Agency
- Applicants: Japan Science and Technology Agency
- Inventors: Yoshihiro KAWAOKA; Tokiko Watanabe; Eiryo Kawakami; Shinji Watanabe
- Web page: https://patentgrep.com/patent/US20190314489A1

## CPC

- A61K 39/145: Orthomyxoviridae, e.g. influenza virus
- C12N 15/111: {General methods applicable to biologically active non-coding nucleic acids}
- C12N 5/00: Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor; (plant reproduction by tissue culture techniques A01H4/00)
- C12N 5/0686: {Kidney cells}
- C12N 5/10: Cells modified by introduction of foreign genetic material
- C12N 7/00: Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof (preparing medicinal viral antigen or antibody compositions, e.g. virus vaccines, A61K39/00)
- C12N 7/02: Recovery or purification
- C12N 7/08: {Inactivation or attenuation} by serial passage of virus
- C12N 15/113: Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; {Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing (when used in plants C12N15/8218)}
- C12N 2310/14: interfering nucleic acids [NA]
- C12N 2320/12: in functional genomics, i.e. for the determination of gene function
- C12N 2510/00: Genetically modified cells
- C12N 2510/02: Cells for production
- C12N 2760/16051: Methods of production or purification of viral material
- C12N 2760/16151: Methods of production or purification of viral material
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

The present invention provides cells which have a high ability to propagate influenza virus, are suitable for use in production of an influenza virus for preparing a vaccine, and are able to be cultured in vitro, and a method for producing an influenza virus using the cells. That is, the present invention provides cells for producing an influenza virus in which expression of one or more genes that encode proteins involved in an effect of suppressing influenza virus production in a cell is suppressed and the gene is at least one selected from the group including ACTG1 gene and the like, and a method for producing an influenza virus that includes infecting the cells for producing an influenza virus with an influenza virus and then culturing.

## Claims

### Claim at position 1

1: Cells for producing an influenza virus which are HEK293 cells, Vero cells, or MDCK cells in which expression of at least one chromosomal gene is suppressed and which are able to be cultured in vitro,
wherein the at least one chromosomal gene is at least one gene selected from the group consisting of ACTG1 gene, ACTN1 gene, CCT6A gene, COPS7B gene, DAP3 gene, ERLIN2 gene, GNAI2 gene, GTF3C5 gene, HNRPAB gene, KHSRP gene, KRTI8 gene, MTCH1 gene, PPP2RIA gene, PRPS1 gene, RAB18 gene, RAB3A gene, RAPIB gene, RPS19 gene, RPS7 gene, S100A10 gene, SFRS7 gene, SLC2A12 gene, TMED2 gene, and USP10 gene.

### Claim at position 2 (depends on 1)

2: The cells according to claim 1,
wherein the gene is deleted or disrupted.

### Claim at position 3 (depends on 1)

3: The cells according to claim 1,
wherein the at least one chromosomal gene is at least one selected from the group including ACTG1 gene, ACTN1 gene, DAP3 gene, GNAI2 gene, GTF3C5 gene, KRT18 gene, MTCH1 gene, PRPS1 gene, RPS19 gene, S100A10 gene, SFRS7 gene, SLC2A12 gene, USP10 gene, PPP2RIA gene, and TMED2 gene.

### Claim at position 4

4-6. (canceled)

### Claim at position 5 (depends on 1)

7: The cells according to claim 1,
wherein the influenza virus is used to be formulated into an influenza virus vaccine.

### Claim at position 6

8-9. (canceled)
